2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells

Blood

Volumn 92, Issue 11, 1998, Pages 4336-4343

  Maran, Avudaiappan ^b   Waller, Cornelius F ^b   Paranjape, Jayashree M ^b   Li, Guiying ^b   Xiao, Wei ^b   Zhang, Kerry ^b   Kalaycio, Matt E ^b   Maitra, Ratan K ^b   Lichtin, Alan E ^b   Brugger, Wolfram ^b   Torrence, Paul F ^b   Silverman, Robert H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; RIBONUCLEASE;

ARTICLE; CELL STRAIN HL 60; CELL STRAIN K 562; CHIMERA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA DEGRADATION;

EID: 0032403447     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.11.4336.423a06_4336_4343     Document Type: Article

References (33)

1. Ho PT, Parkinson DR: Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol 24:187, 1997
2. De Fabritiis P, Calabretta B: Antisense oligonucleotides for the treatment of chronic myelogenous leukemia: Are they still a promise? Haematologica 80:295, 1995
3. Snyder DS, Wu Y, Wang JL, Rossi JJ, Swiderski P, Kaplan BE, Forman SJ: Ribozyme-rnediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 82:600, 1993
4. bcr-abl expression and inhibit the proliferation of BCR/ABL-containing cell lines. Blood 81:502, 1993
5. Konopka JB, Witte ON: Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol 5:3116, 1985
6. bcr/abl gene of the Philadelphia chromosome. Science 247:824, 1990
7. Elefanty AG, Hariharan IK, Cory S: bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 9:1069, 1990
8. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG: Bcr-abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83:1179, 1994
9. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83:2083, 1994
10. 1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 91:4504, 1994
11. Ratajczak MZ, Kant JA, Luger SM, Hijiya N, Zhang J, Zon G, Gewirtz AM: In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 89:11823, 1992
12. 1 leukemia in severe combined immunodeficient mice by a combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J Natl Cancer Inst 89:124, 1997
13. Skorski T, Nieborowska-Skorska M, Campbell K, Iozzo RV, Zon G, Darzynkiewicz Z, Calabretta B: Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. J Exp Med 182:1645, 1995
14. De Fabritiis P, Petti MC, Montefusco E, De Propris MS, Sala R, Bellucci R, Mancini M, Lisci A, Bonetto F, Geiser T, Calabretta B, Mandelli F: BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 91:3156, 1998
15. Tari AM, Tucker SD, Deisseroth A, Lopez-Bernstein G: Liposomal delivery of methylphosphonate antisense oligonucleotides in chronic myelogenous leukemia. Blood 84:601, 1994
16. Bergan RC, Kyle E, Connell Y, Neckers L: Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxyribonucleotides. Antisense Res Dev 5:33, 1995
17. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Mariat P: Bcr-abl antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood 86:3891, 1995
18. Torrence PF, Maitra RK, Lesiak K, Khamnei S, Zhou A, Silverman RH: Targeting RNA for degradation with a 2′,5′-oligoadenylate-antisense chimera. Proc Natl Acad Sci USA 90:1300, 1993
19. Silverman RH: 2-5A dependent RNase L: A regulated endoribonuclease in the interferon system, in D'Alessio G, Riordan JF (eds): Ribonucleases: Structure and Function. San Diego, CA, Academic, 1997, p 515
20. Torrence PF, Xiao W, Li G, Khamnei S: Development of 2′,5′-oligoadenylates as potential therapeutic agents. Curr Med Chem 1:176, 1994
21. Maran A, Maitra RK, Kumar A, Dong B, Xiao W, Li G, Williams BRG, Torrence PF, Silverman RH: Blockage of NF-kB signaling by selective ablation of an mRNA target by 2-5A-antisense. Science 265:789, 1994
22. Maitra RK, Li G, Xiao W, Dong B, Torrence PF, Silverman RH: Catalytic cleavage of an RNA target by 2-5A-antisense and 2-5A dependent RNase. J Biol Chem 270:15071, 1995
23. Cirino NM, Li G, Xiao W, Torrence PF, Silverman RH: Targeting RNA decay with 2′,5′-oligoadenylate-antisense in respiratory syncytial virus infected cells. Proc Natl Acad Sci USA 94:1937, 1997
24. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B: Selective inhibition of leukemia cell proliferation by BCR/ABL antisense oligodeoxynucleotides. Science 253:562, 1991
25. Lesiak K, Khamnei S, Torrence PF: 2′,5′-Oligoadenylate-antisense chimeras: Synthesis and Properties. Bioconjugate Chem 4:467, 1993
26. Xiao W, Li G, Lesiak K, Dong B, Silverman RH, Torrence PF: Synthesis of a 5′-thiophosphate analogue of 2-5A, a phosphatase resistant activator of the 2-5A-dependent ribonuclease. Bioorg Med Chem Lett 4:2609, 1994
27. Xiao W, Player MR, Li G, Zhang K, Lesiak K, Torrence PF: Synthesis and characterization of composite nucleic acids containing 2′,5′-oligoriboadenylate linked to antisense DNA. Antisense Nucleic Acid Drug Devel 6:247, 1996
28. Li G, Xiao W, Torrence PF: Synthesis and properties of second generation 2-5A-antisense chimeras with enhanced resistance to exonucleases. J Med Chem 40:2959, 1997
29. Xiao W, Li G, Player MR, Maitra RK, Waller CF, Silverman RH, Torrence PF: Nuclease-resistant composite 2′,5′-oligoadenylate-3′, 5′-oligonucleotides for the targeted destruction of RNA: 2-5A-iso-antisense. J Med Chem 41:1531, 1998
30. Zhou A, Hassel BA, Silverman RH: Expression cloning of 2-5A-dependent RNase-A uniquely regulated mediator of interferon action. Cell 72:753, 1993
31. Dong B, Xu L, Zhou A, Hassel BA, Lee X, Torrence PF, Silverman RH: Intrinsic molecular activities of the interferon-induced 2-5A-dependent RNase. J Biol Chem 269:14153, 1994
32. bcr/abl expression in K562 cells by electroporation with an antisense oligonucleotide. Leuk Lymphoma 3:201, 1990
33. Ratajczak MZ, Hijiya N, Catani L, DeRiel K, Luger SM, McGlave P, Gewirtz AM: Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are sensitive to the growth inhibitory effects of c-myb antisense oligonucleotides. Blood 79:1956, 1992